VIENNA, Austria and KING OF PRUSSIA, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, reported today its financial results for the quarter ended March 31, 2016.
“We continue enrolling patients in our lefamulin development program for the treatment of patients with moderate to severe Community Acquired Bacterial Pneumonia (CABP),” said Dr. Colin Broom, Chief Executive Officer of Nabriva. “Our balance sheet remains strong and we have over $100 million in cash that we expect to be sufficient to fund our operations at least through the receipt of top-line phase 3 clinical trial data, which is anticipated in the second half of 2017.”
“We continue enrolling patients in our lefamulin development program for the treatment of patients with moderate to severe Community Acquired Bacterial Pneumonia (CABP),” said Dr. Colin Broom, Chief Executive Officer of Nabriva. “Our balance sheet remains strong and we have over $100 million in cash that we expect to be sufficient to fund our operations at least through the receipt of top-line phase 3 clinical trial data, which is anticipated in the second half of 2017.”